Arkansas judge Tim Fox, who ruled earlier this year that Janssen Pharmaceuticals and its parent company Johnson & Johnson had concealed risks associated with their antipsychotic Risperdal and levied a fine of $1.2 billion, has denied a J&J request for a new trial. In other news, sources say that J&J is within two weeks of a final settlement with federal prosecutors to resolve allegations of using deceptive tactics to market Risperdal. J&J hopes to avoid a felony charge that would prevent it from marketing Risperdal to government health programs such as medicare.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.